{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:49:41Z","timestamp":1791049781140,"version":"4.1.0"},"reference-count":35,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Breast cancer tumors possess intratumoral heterogeneity (ITH), which is associated with therapeutic resistance. Tumors with high ITH exhibit human epidermal growth factor receptor 2 (HER2) heterogeneity, affecting the effectiveness of HER2-targeted therapies. Our recent study identified HER2 ITH as an independent prognostic factor for poor outcomes in HER2-positive breast cancer. We here investigated the association between HER2 ITH and anti-HER2 neoadjuvant chemotherapy (NAC) resistance. Methods: This study included 97 patients with primary HER2-positive breast cancer treated with anti-HER2 NAC. Breast tumor samples were obtained from vacuum-assisted breast biopsy before NAC. HER2 gene amplification was assessed using fluorescence in situ hybridization (FISH), and HER2 gene copy number histograms were generated. Using the Gaussian mixture model, histogram data were analyzed and categorized into the high (HH) and low HER2 heterogeneity (LH) groups. The association between HER2 ITH and treatment response was evaluated using the pathological complete response (pCR) rate. Results: Of the 97 patients, 18 (18.6%) and 79 (81.4%) were classified into the HH and LH groups, respectively. The pCR rate in the HH group was significantly lower at 28% (5\/18) than that in the LH group at 65% (51\/79) (p &lt; 0.01). Multivariate analysis of pathological parameters revealed that the most significant predictor of pCR rate was HER2 ITH (p = 0.02). Conclusions: HER2 ITH assessment may be valuable in predicting therapeutic outcomes in HER2-positive breast cancer. Our novel approach of the HER2 ITH method using FISH histograms could serve as a useful tool for predicting anti-HER2 NAC resistance.<\/jats:p>","DOI":"10.3390\/cancers17132126","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T12:05:40Z","timestamp":1750766740000},"page":"2126","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["High HER2 Intratumoral Heterogeneity Is Resistant to Anti-HER2 Neoadjuvant Chemotherapy in Early Stage and Locally Advanced HER2-Positive Breast Cancer"],"prefix":"10.3390","volume":"17","author":[{"given":"Takaaki","family":"Hatano","sequence":"first","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-15 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Tanei","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-15 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3861-6444","authenticated-orcid":false,"given":"Shigeto","family":"Seno","sequence":"additional","affiliation":[{"name":"Department of Bioinformatic Engineering, Graduate School of Information Science and Technology, Osaka University, 1-5 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-652X","authenticated-orcid":false,"given":"Yoshiaki","family":"Sota","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-15 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-5107","authenticated-orcid":false,"given":"Nanae","family":"Masunaga","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-15 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieko","family":"Mishima","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-15 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3284-0833","authenticated-orcid":false,"given":"Masami","family":"Tsukabe","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-15 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-15 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-15 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0832-9877","authenticated-orcid":false,"given":"Masafumi","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-15 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Shimazu","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-15 Yamadaoka, Suita 565-0871, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Turashvili, G., and Brogi, E. (2017). Tumor Heterogeneity in Breast Cancer. Front. Med., 4.","DOI":"10.3389\/fmed.2017.00227"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000477851","article-title":"Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine","volume":"85","author":"Aleskandarany","year":"2018","journal-title":"Pathobiology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-319-22909-6_7","article-title":"Intratumor Heterogeneity in Breast Cancer","volume":"882","author":"Beca","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1615\/CritRevOncog.2020036150","article-title":"Breast HER2 Intratumoral Heterogeneity as a Biomarker for Improving HER2-Targeted Therapy","volume":"25","author":"Nitta","year":"2020","journal-title":"Crit. Rev. Oncog."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1002\/cjp2.346","article-title":"AI-based intra-tumor heterogeneity score of Ki67 expression as a prognostic marker for early-stage ER+\/HER2- breast cancer","volume":"10","author":"Lu","year":"2024","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"112953","DOI":"10.1016\/j.ejca.2023.112953","article-title":"Transcriptional intra-tumour heterogeneity predicted by deep learning in routine breast histopathology slides provides independent prognostic information","volume":"191","author":"Wang","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.4103\/jcrt.jcrt_1166_21","article-title":"Intratumoral heterogeneity contributes to the chemotherapy prognosis of breast cancer","volume":"18","author":"Li","year":"2022","journal-title":"J. Cancer Res. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/bcr3658","article-title":"Breast cancer intra-tumor heterogeneity","volume":"16","author":"Martelotto","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ajcp\/aqz010","article-title":"Pathologic Features and Clinical Implications of Breast Cancer with HER2 Intratumoral Genetic Heterogeneity","volume":"152","author":"Muller","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ctrv.2017.09.001","article-title":"Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?","volume":"60","author":"Miglietta","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11864-023-01070-7","article-title":"Individualizing Curative-Intent Therapy in HER2-Positive Early-Stage Breast Cancer","volume":"24","author":"Waks","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1007\/s12032-012-0242-8","article-title":"Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab\/taxanes but not disease-free survival in HER2-positive breast cancer patients","volume":"29","author":"Zhang","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.1002\/cam4.5788","article-title":"Intratumoral heterogeneity, treatment response, and survival outcome of ER-positive HER2-positive breast cancer","volume":"12","author":"Teruya","year":"2023","journal-title":"Cancer Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tanei, T., Seno, S., Sota, Y., Hatano, T., Kitahara, Y., Abe, K., Masunaga, N., Tsukabe, M., Yoshinami, T., and Miyake, T. (2024). High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer. Cancers, 16.","DOI":"10.20944\/preprints202402.1136.v1"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2013.103","article-title":"HER2 in situ hybridization in breast cancer: Clinical implications of polysomy 17 and genetic heterogeneity","volume":"27","author":"Hanna","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1309\/AJCPXTZSKBRIP07W","article-title":"Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: Time for a new look at how to report heterogeneity","volume":"136","author":"Allison","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/modpathol.2011.206","article-title":"\u2018Genetic heterogeneity\u2019 in HER2\/neu testing by fluorescence in situ hybridization: A study of 2,522 cases","volume":"25","author":"Chang","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10549-020-05650-1","article-title":"HER2 intratumoral heterogeneity is independently associated with distal metastasis and overall survival in HER2-positive breast carcinomas","volume":"181","author":"Shen","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/1878-0261.12650","article-title":"Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification","volume":"14","author":"Agahozo","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e193692","DOI":"10.1001\/jamaoncol.2019.3692","article-title":"Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients with Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial","volume":"6","author":"Shao","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1158\/2159-8290.CD-21-0936","article-title":"Heterogeneous HER2 Amplification-a New Clinical Category of HER2-Positive Breast Cancer?","volume":"11","author":"Okines","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.17116\/patol20198106149","article-title":"HER2\/neu gene amplification as a mechanism of clonal heterogeneity in breast cancer","volume":"81","author":"Pavlenko","year":"2019","journal-title":"Arkh Patol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/apm.13076","article-title":"Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPAwith HER2, I.H.C.; HER2, F.I.S.H","volume":"128","author":"Jensen","year":"2020","journal-title":"APMIS"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00428-021-03036-2","article-title":"Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer","volume":"479","author":"Horii","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-017-4453-8","article-title":"HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma","volume":"166","author":"Hou","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7196","DOI":"10.1158\/1078-0432.CCR-09-0585","article-title":"Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines","volume":"15","author":"Gu","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1074\/mcp.M400221-MCP200","article-title":"Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2\/neu-positive breast cancer","volume":"4","author":"Zhang","year":"2005","journal-title":"Mol. Cell. Proteom."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1074\/mcp.O115.049049","article-title":"Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues","volume":"14","author":"Steiner","year":"2015","journal-title":"Mol. Cell. Proteom."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101203","DOI":"10.1016\/j.xcrm.2023.101203","article-title":"Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2+ breast cancer","volume":"4","author":"Debets","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2126\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:58:03Z","timestamp":1760032683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":35,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cancers17132126"],"URL":"https:\/\/doi.org\/10.3390\/cancers17132126","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]}}}